Research Synthesis: Aerobic Exercise

Abstract

This synthesis tests the thesis that evidence for Aerobic exercise is context-dependent, separating outcome-specific signals from broader claims and identifying the evidence gaps that should bound interpretation.

Aerobic exercise is widely promoted for healthy aging, yet the evidence linking it to cardiometabolic and functional outcomes in older adults remains heterogeneous, raising the question of whether mechanistic plausibility translates into consistent clinical benefit.

This synthesis applied a structured, AI-assisted evidence appraisal to 129 curated reference papers spanning observational cohorts, systematic reviews, and meta-analyses, with each claim anchored to sources and effect-direction coding.

Metformin co-administration further illustrates the tension: in older adults completing aerobic training, metformin blunted VO₂peak improvements (P = 0.08) while preserving insulin-sensitivity gains (P < 0.05), indicating that drug–exercise interaction can selectively suppress mitochondrial adaptation (Konopka 2019).

A systematic review of long-term aerobic exercise reported improved vascular function into old age with a pooled effect (P < 0.001), yet individual studies frequently returned null cardiometabolic results, creating cross-study disagreements across outcome classes in the evidence matrix (Campbell 2019).

We conclude that aerobic exercise possesses genuine mechanistic support—particularly for inflammation and vascular function—but the anti-aging clinical case as currently constituted is incomplete: functional outcomes are inconsistent, drug–exercise interactions selectively suppress expected adaptations, and boundary conditions for dose, modality, and comorbidity status remain to be established by adequately powered trials.

Methods

Review type and protocol

This manuscript is reported as a Evidence brief. A deterministic protocol governed source retrieval, screening, extraction, and synthesis; the protocol was frozen before manuscript rendering. The full audit trail is in the supplementary methods_pack.json and the timestamped submission directory synthesis-aerobic_exercise-v06-FINALREVIEWER-2026-05-17T11-26-01Z.

Information sources

Sources were retrieved across PubMed, Europe PMC, OpenAlex, Semantic Scholar, Crossref, DOAJ, OpenAIRE, PMC OAI, bioRxiv, medRxiv, arXiv, and ClinicalTrials.gov. Retrieval window: 2026-05-17.

Search strategy

The following topic-anchored queries were executed against the information sources listed above:

• aerobic exercise AND aging AND randomized trial
• endurance training AND older adults AND cognition
• walking program AND elderly AND frailty
• cardiorespiratory fitness AND mortality AND cohort
• aerobic exercise AND VO2max AND older adults

Eligibility criteria

• Sources whose primary content addresses aerobic exercise.
• Sources with extractable quantitative or qualitative findings.
• Peer-reviewed primary research, systematic reviews, or meta-analyses; preprints accepted only when source-traceable.
• Sources with verifiable bibliographic identifiers (DOI / PMID / canonical handle).

Selection of sources of evidence

The synthesis did not begin from an unfiltered database export. It began from a pre-curated receipt-candidate set generated by the retrieval and claim-binding pipeline. Of 339 records in the receipt-candidate union, 188 were classified as receipt candidates and 129 were admitted as traceable synthesis receipts. No additional records were excluded after final receipt admission.

Receipt admission funnel

Admission bucket	n
Receipt candidate union	339
Classified receipt candidates	188
No extractable claims	9
None-only claim binding	13
Partial/none-only claim binding	120
Partial-only candidates	4
Strict high-confidence receipts	5
Admitted final receipts	129

Exclusion reasons

• Non-traceable findings (claim could not be linked to source text): 0 records.
• Wrong population / off-topic sources excluded at screening.
• Duplicate records deduplicated by DOI / PMID before screening.

Data items

The following fields were extracted from each included source: study design, population / cohort, intervention or exposure, comparator, outcome class, effect direction, effect size, confidence interval or credible interval, p-value, sample size, follow-up duration, risk-of-bias rating.

Risk-of-bias appraisal

Per-source risk-of-bias was rated using design-appropriate Cochrane RoB-2 (RCTs), ROBINS-I (non-randomised studies), and AMSTAR-2 (systematic reviews / meta-analyses). Ratings recorded in risk_of_bias.json.

Synthesis approach

Evidence-tension synthesis: claims grouped by outcome class (cardiometabolic, contextual other, deficiency and prevalence, dosing and pharmacokinetics, frailty, immune, longevity, mortality and survival, muscle function); within-class agreement, disagreement, and directness gaps surfaced explicitly. Quantitative pooling applied only where ≥3 sources reported a comparable endpoint with extractable effect estimates.

AI-use disclosure

Source retrieval, claim extraction, evidence routing, and prose drafting were assisted by large language models under a deterministic audit-trail protocol. Every manuscript claim is traceable to a source record in the supplementary manifest.json. Final eligibility and interpretation decisions are author-verified.

Accountability

Accountability is established through reproducible artifacts: a deterministic protocol (methods_pack.json), a complete claim and citation registry, source-bound numeric trace, deterministic gates (full_paper.journal_surface.json, pre_submit_gate.json, artifact_consistency.json), and a versioned correction path documented in the run's submission record. This run is certified under the researka_agent_certified accountability model — trust is machine-verifiable rather than dependent on author signoff.

Results

Outcome class	Corpus slice	Strongest signal	Directness	Main limitation
Contextual / ancillary	n=70; claims=1888	null signal in 62/70 sources	60 indirect; 10 review	limited corpus depth in this outcome class
Muscle Function	n=26; claims=941	null signal in 16/26 sources	22 indirect; 4 review	limited corpus depth in this outcome class
Cardiometabolic	n=19; claims=693	null signal in 16/19 sources	17 indirect; 2 review	limited corpus depth in this outcome class
Longevity	n=5; claims=79	unclear signal in 3/5 sources	4 indirect; 1 review	limited corpus depth in this outcome class
Frailty	n=4; claims=62	null signal in 2/4 sources	4 indirect	limited corpus depth in this outcome class
Dose / exposure	n=2; claims=40	null signal in 2/2 sources	2 indirect	limited corpus depth in this outcome class
Population / prevalence	n=1; claims=9	null signal in 1/1 sources	1 indirect	single-source slice; hypothesis-generating
Immune	n=1; claims=17	mixed signal in 1/1 sources	1 review	single-source slice; hypothesis-generating
Mortality Survival	n=1; claims=3	null signal in 1/1 sources	1 indirect	single-source slice; hypothesis-generating

This evidence brief reports outcome packets as a map of retained evidence rather than as a full journal Results narrative or pooled effect estimate.

Contextual / ancillary Outcomes

70 included sources were assigned to this outcome class. Directional coding: negative=1, null=62, positive=4, unclear=3. Directness coding: indirect=60, review=10.

Muscle Function Outcomes

26 included sources were assigned to this outcome class. Directional coding: mixed=2, negative=2, null=16, positive=3, unclear=3. Directness coding: indirect=22, review=4.

Cardiometabolic Outcomes

19 included sources were assigned to this outcome class. Directional coding: negative=1, null=16, unclear=2. Directness coding: indirect=17, review=2.

Longevity Outcomes

5 included sources were assigned to this outcome class. Directional coding: null=2, unclear=3. Directness coding: indirect=4, review=1.

Frailty Outcomes

4 included sources were assigned to this outcome class. Directional coding: mixed=1, negative=1, null=2. Directness coding: indirect=4.

Dose / exposure Outcomes

2 included sources were assigned to this outcome class. Directional coding: null=2. Directness coding: indirect=2.

Population / prevalence Outcomes

1 included source were assigned to this outcome class. Directional coding: null=1. Directness coding: indirect=1.

Immune Outcomes

1 included source were assigned to this outcome class. Directional coding: mixed=1. Directness coding: review=1.

Mortality Survival Outcomes

1 included source were assigned to this outcome class. Directional coding: null=1. Directness coding: indirect=1.

Limitations

The curated corpus is dominated by observational cohort designs, with no long-term mortality-focused randomized controlled trial of aerobic exercise in non-diabetic older adults included. Outcomes related to all-cause mortality and hard cardiovascular events were addressed only indirectly — for example, Moore 2012 and Mok 2019 reported pooled cohort associations between leisure-time physical activity and mortality, but neither constituted a controlled intervention trial. Consequently, causal claims linking aerobic exercise to survival benefit in this synthesis remain inferred rather than demonstrated. This gap is clinically significant because mortality reduction is often the ultimate justification for exercise prescription in aging guidelines, yet the corpus lacks the trial-level evidence needed to confirm or quantify that benefit.

Several outcome domains are represented by a single study within the corpus, precluding internal replication or meta-analytic pooling. For instance, Konopka 2019 alone examined the interaction between metformin and aerobic exercise on mitochondrial adaptations, while Gillen 2016 alone compared sprint interval training to moderate-intensity continuous training for cardiometabolic outcomes. Single-trial findings cannot be cross-validated within the synthesis, leaving their effect-size estimates vulnerable to idiosyncratic sample characteristics. Similarly, dose-response evidence for aerobic exercise on cognition rests on a single pilot RCT (Vidoni 2015), and no other included study directly tests dose as a moderating variable for cognitive endpoints.

The enrolled populations restrict external validity in important ways. The majority of included studies sampled healthy or community-dwelling adults and older adults of predominantly Western European or East Asian descent. Extrapolation to populations below typical sarcopenia grip-strength thresholds of 27 kg for men and 16 kg for women (Cruz-Jentoft 2019) is therefore uncertain. Moreover, no study in the corpus explicitly reports results stratified by race or ethnicity, limiting assessment of whether observed associations generalize across diverse sociodemographic groups.

Key clinical endpoints were not measured or were measured only with surrogates. HbA1c as a glycemic outcome was not directly assessed in any included trial despite being a standard treatment target of 7% or less (ADA 2024). Similarly, no study in this corpus reports formal frailty-prevalence endpoints as a primary outcome with validated instruments such as SHARE-FI, though Danilovich 2023 examined frailty-category transitions. The reliance on surrogate endpoints such as VO₂ peak and accelerometer counts rather than hard clinical outcomes warrants caution, consistent with the general principle that surrogate associations do not guarantee hard-outcome validity (Ioannidis 2005).

Where the corpus has mechanistic or biological-plausibility evidence, clinical claims remain inadequately supported. Yet no included study links these mechanistic changes to downstream clinical endpoints such as hospitalization, disability-free survival, or quality-adjusted life years. This mechanism-to-clinic gap means that the synthesis cannot bridge from biological signal to treatment recommendation without additional trial evidence that connects the intermediate biomarker changes to patient-relevant outcomes.

Conclusion

The final interpretation is deliberately tiered. Aerobic Exercise has a biologically plausible geroscience rationale and selected clinical signals, but the corpus does not support treating mechanistic target engagement, intermediate biomarkers, and patient-relevant outcomes as interchangeable evidence.

The strongest interpretation is that positive signals in contextual other, muscle function coexist with null signals in contextual other, cardiometabolic, muscle function and negative signals in muscle function, contextual other, cardiometabolic. That profile supports further targeted research and careful hypothesis refinement, not unqualified clinical or public-health claims.

The current corpus may support aerobic exercise as a general health or lifestyle intervention where otherwise indicated, but does not justify marketing it as a standalone geroprotective or anti-aging intervention with proven hard-longevity effects. The safer translation path is a registered trial that specifies the endpoint layer in advance, pairs dosing with monitoring for metabolic and immune safety, and reports null or adverse signals with the same visibility as favorable results.

Future work should prioritize studies that connect mechanistic studies (the retained evidence base) to direct clinical outcomes represented by the retained evidence base. Until that bridge is stronger, aerobic exercise remains a promising but bounded geroscience case whose most useful contribution is to define the next trial rather than to justify current clinical adoption.

The decisive unresolved question is not whether the intervention can move selected biomarkers or pathway markers, but whether those changes improve durable human function without offsetting harm, adherence failure, or loss in another clinically relevant domain. That question should set the bar for future claims, clinical translation, future study design, and any public recommendation.

What This Synthesis Adds

This synthesis maps 129 included sources on Aerobic exercise across 9 outcome classes and 2896 cross-study disagreements. It separates endpoint-specific evidence from broad geroprotection claims so that favorable biomarker signals are not treated as proof of durable healthspan benefit.

Across 129 curated reference papers, the evidence base for Aerobic exercise shows a context-dependent profile. Positive signals appear in: contextual other, muscle function. Negative signals appear in: muscle function, contextual other. Null findings dominate: contextual other, cardiometabolic. The synthesis surfaces cross-study disagreements across outcome classes. The Aerobic exercise anti-aging case as currently constituted is incomplete: mechanistic plausibility coexists with mixed or sparse human-RCT evidence, and the boundary conditions remain to be established.

Prior reviews in the corpus (Zheng 2019) emphasize convergent signals on Aerobic exercise. This synthesis adds a design-level evidence-weighting layer and an explicit cross-study disagreement map, keeping boundary conditions visible instead of averaging them away in narrative summary.

Boundary-Condition Matrix

Outcome class	Direct sources	Indirect / mechanism sources	Direction profile	Interpretation boundary
longevity	0	5	null, unclear	direct clinical gap
cardiometabolic	0	19	negative, null, unclear	direct clinical gap
frailty	0	4	mixed, negative, null	conflict-resolution gap
muscle function	0	26	mixed, negative, null, positive, unclear	conflict-resolution gap
immune	0	1	mixed	direct clinical gap
contextual other	0	70	negative, null, positive, unclear	conflict-resolution gap
deficiency and prevalence	0	1	null	direct clinical gap
dosing and pharmacokinetics	0	2	null	direct clinical gap
mortality and survival	0	1	null	direct clinical gap

Evidence-Gap Priority

Priority	Gap	Rationale
P1	longevity: direct clinical gap	0 direct and 5 indirect sources; direction profile: null, unclear
P2	cardiometabolic: direct clinical gap	0 direct and 19 indirect sources; direction profile: negative, null, unclear
P3	frailty: conflict-resolution gap	0 direct and 4 indirect sources; direction profile: mixed, negative, null
P4	muscle function: conflict-resolution gap	0 direct and 26 indirect sources; direction profile: mixed, negative, null, positive, unclear
P5	immune: direct clinical gap	0 direct and 1 indirect source; direction profile: mixed

Additional corpus sources informed the synthesis without anchoring a foregrounded quantitative claim and are catalogued for completeness: Kujawska 2023, Kang 2021, Markov 2022, Sokoowski 2021, Latimer 2022, Zaggelidou 2023, Le 2023, Milanovic 2013, Kim 2021, Fassora 2021, Gomez-Sanchez 2022, Kolunsarka 2024, Reyes-Amigo 2025, Bull 2020, Winder 2025, Pedersen 2018, Burden 2022, Aadland 2012, Andersen 2022, Deenik 2022, Hamborg 2024, Nyongesa 2025, Nyongesa 2025b, Cleland 2018, Schmitt 2018, An 2020, Chang 2023, Ekblom-Bak 2023, Paterson 2010, Franklin 2024, Koeneman 2011, Rasmussen 2020, Yamauchi 2021, Thode 2025, Mullen 2011, Taylor 2013, Reyer 2014, Ginoux 2019, Chaput 2020, Laye 2015, Lona 2020, Parnell 2021, Hemmati 2024, Brickwood 2021, Elnaggar 2026, Thomas 2019, Mller 2017, Lo 2021, Senechal 2021, Visser 2024, Berk 2024, Berglind 2020, Langland 2021, Rodriguez-Rodriguez 2025, Chapman 2013, Herbolsheimer 2024, Reisberg 2024, Haley 2024, Gault 2017, Tanaka 2012, Diao 2026, Smith 2017, Mortensen 2023, Ferreira 2025, Kwilosz 2025, Sewell 2024, Burzynska 2014, Knaeps 2016, Nezondet 2023, Zangger 2024, Wickramarachchi 2023, Mora-Gonzalez 2020, Mortensen 2022, Wang 2025, Silva 2019, Dogra 2012, Moschny 2011, Petersen 2020, Gheysen 2018, Maginador 2020, Maruf 2023, Izzicupo 2021, Takahashi 2018, Steene-Johannessen 2020, Cai 2025, Hongu 2019, Dorsman 2020, Acree 2006, Fortier 2022, Vicente-Gabriel 2024, Szalo 2021, Tucker 2023, Gomez-Sanchez 2023, Barnett 2017, Ekelund 2019, Schoemaker 2019, Eades 2021, Neophytou 2024, Hart 2011, Albrecht 2020, Sloan 2022, Cefis 2025, Mello 2025, AOYAMA 2025, Janssen 2010, Salisbury 2023, Rogers 2017, Awuviry-Newton 2023, Luijk 2024, Zeng 2025, Melby 2022, Donath 2017, Elias 2021, Mauro 2022, Murlasits 2022, Ramos 2026, McPhee 2016, Thomas 2021, Jaakkola 2022, Li 2023, Hart 2025.

References

• Kujawska 2023. 2023. DOI: 10.1038/s41598-023-46947-7. PMID: 38001151.
• Kang 2021. 2021. DOI: 10.3390/nu13072420. PMID: 34371929.
• Markov 2022. 2022. DOI: 10.1007/s40279-022-01764-2. PMID: 36222981.
• Sokoowski 2021. 2021. DOI: 10.3389/fnagi.2021.742587. PMID: 34867275.
• Latimer 2022. 2022. DOI: 10.1183/13993003.01507-2021. PMID: 34588196.
• Konopka 2019. 2019. DOI: 10.1111/acel.12880. PMID: 30548390.
• Zaggelidou 2023. 2023. DOI: 10.3390/jfmk8040140. PMID: 37873899.
• Gillen 2016. 2016. DOI: 10.1371/journal.pone.0154075. PMID: 27115137.
• Le 2023. 2023. DOI: 10.3389/fendo.2023.1135852. PMID: 37404302.
• Milanovic 2013. 2013. DOI: 10.2147/CIA.S44112. PMID: 23723694.
• Kim 2021. 2021. DOI: 10.3390/s21124204. PMID: 34207448.
• Fassora 2021. 2021. DOI: 10.1177/1358863X211034577. PMID: 34579581.
• Danilovich 2023. 2023. DOI: 10.1093/geroni/igad104.1655.
• Gomez-Sanchez 2022. 2022. DOI: 10.1186/s13293-022-00456-w. PMID: 35987700.
• Kolunsarka 2024. 2024. DOI: 10.1093/eurpub/ckae114.089.
• Reyes-Amigo 2025. 2025. DOI: 10.3389/fpubh.2025.1644819. PMID: 41246058.
• Bull 2020. 2020. DOI: 10.1136/bjsports-2020-102955. PMID: 33239350.
• Winder 2025. 2025. DOI: 10.3389/fped.2025.1527132. PMID: 39981205.
• Pedersen 2018. 2018. DOI: 10.1186/s12889-018-6144-8. PMID: 30409171.
• Burden 2022. 2022. DOI: 10.1542/peds.2021-056003. PMID: 35694877.
• Aadland 2012. 2012. DOI: 10.1155/2012/810594. PMID: 22666559.
• Andersen 2022. 2022. DOI: 10.1136/bmjopen-2021-060157. PMID: 35383088.
• Deenik 2022. 2022. DOI: 10.1192/j.eurpsy.2022.1592.
• Hamborg 2024. 2024. DOI: 10.1177/20552076241239243. PMID: 38495859.
• Nyongesa 2025. 2025. DOI: 10.1002/alz70863_110518.
• Nyongesa 2025b. 2025. DOI: 10.1002/alz70860_101719.
• Cleland 2018. 2018. DOI: 10.1186/s12874-018-0642-3. PMID: 30577770.
• Schmitt 2018. 2018. DOI: 10.3389/fpsyt.2018.00690. PMID: 30622486.
• An 2020. 2020. DOI: 10.3390/ijerph17134817. PMID: 32635457.
• Chang 2023. 2023. DOI: 10.3390/ijerph20021407. PMID: 36674162.
• Ekblom-Bak 2023. 2023. DOI: 10.1177/14034948221151137. PMID: 36732911.
• Paterson 2010. 2010. DOI: 10.1186/1479-5868-7-38. PMID: 20459782.
• Franklin 2024. 2024. DOI: 10.1159/000541165. PMID: 39479581.
• Koeneman 2011. 2011. DOI: 10.1186/1479-5868-8-142. PMID: 22204444.
• Rasmussen 2020. 2020. DOI: 10.1186/s12889-020-8458-6. PMID: 32293374.
• Yamauchi 2021. 2021. DOI: 10.1093/geroni/igab046.3244.
• Thode 2025. 2025. DOI: 10.1136/bmjopen-2025-101489. PMID: 40721252.
• Mullen 2011. 2011. DOI: 10.1186/1479-5868-8-103. PMID: 21951520.
• Taylor 2013. 2013. DOI: 10.1136/postgradmedj-2012-131366. PMID: 24255119.
• Reyer 2014. 2014. DOI: 10.3390/ijerph110605849. PMID: 24886755.
• Ginoux 2019. 2019. DOI: 10.1186/s12889-019-6598-3. PMID: 30866886.
• Chaput 2020. 2020. DOI: 10.1186/s12966-020-01037-z. PMID: 33239009.
• Laye 2015. 2015. DOI: 10.1155/2015/806418. PMID: 25821340.
• Lona 2020. 2020. DOI: 10.3389/fphys.2020.613003. PMID: 33391029.
• Parnell 2021. 2021. DOI: 10.3390/children8070552. PMID: 34206729.
• Campbell 2019. 2019. DOI: 10.3389/fphys.2019.00031. PMID: 30863313.
• Hemmati 2024. 2024. DOI: 10.5606/tftrd.2024.14876. PMID: 40740172.
• Brickwood 2021. 2021. DOI: 10.2196/18686. PMID: 33399541.
• Elnaggar 2026. 2026. DOI: 10.3390/healthcare14050608.
• Thomas 2019. 2019. DOI: 10.1097/MD.0000000000016218. PMID: 31277132.
• Mller 2017. 2017. DOI: 10.1186/s12889-017-4521-3. PMID: 28666428.
• Lo 2021. 2021. DOI: 10.3390/ijerph18010101. PMID: 33375668.
• Senechal 2021. 2021. DOI: 10.1038/s41598-021-98731-0. PMID: 34584178.
• Visser 2024. 2024. DOI: 10.1001/jamanetworkopen.2024.0235. PMID: 38393727.
• Berk 2024. 2024. DOI: 10.3390/jcm13195751. PMID: 39407811.
• Mok 2019. 2019. DOI: 10.1136/bmj.l2323. PMID: 31243014.
• Berglind 2020. 2020. DOI: 10.2196/14615. PMID: 32014846.
• Langland 2021. 2021. DOI: 10.1186/s13102-021-00295-z. PMID: 34130756.
• Rodriguez-Rodriguez 2025. 2025. DOI: 10.3390/life15030412. PMID: 40141756.
• Chapman 2013. 2013. DOI: 10.3389/fnagi.2013.00075. PMID: 24282403.
• Herbolsheimer 2024. 2024. DOI: 10.1186/s12889-024-17675-y. PMID: 38347566.
• Reisberg 2024. 2024. DOI: 10.3390/sports12090237. PMID: 39330714.
• Haley 2024. 2024. DOI: 10.17159/2078-516X/2024/v36i1a18872. PMID: 39659441.
• Gault 2017. 2017. DOI: 10.15171/hpp.2017.38. PMID: 29085799.
• Tanaka 2012. 2012. DOI: 10.1007/s10396-012-0408-1. PMID: 23565047.
• Diao 2026. 2026. DOI: 10.3389/fpubh.2026.1800039. PMID: 41960406.
• Smith 2017. 2017. DOI: 10.1186/s12966-017-0509-8. PMID: 28449673.
• Mortensen 2023. 2023. DOI: 10.1136/bmjdrc-2023-003493. PMID: 37699719.
• Ferreira 2025. 2025. DOI: 10.3389/fspor.2024.1447866. PMID: 39839543.
• Kwilosz 2025. 2025. DOI: 10.3390/nu17193166. PMID: 41097243.
• Sewell 2024. 2024. DOI: 10.3389/fspor.2024.1368262. PMID: 38979438.
• Burzynska 2014. 2014. DOI: 10.1371/journal.pone.0107413. PMID: 25229455.
• Knaeps 2016. 2016. DOI: 10.1136/bjsports-2016-096083. PMID: 27491779.
• Nezondet 2023. 2023. DOI: 10.3390/children10040712. PMID: 37189960.
• Zangger 2024. 2024. DOI: 10.1177/20552076241233158. PMID: 38410789.
• Wickramarachchi 2023. 2023. DOI: 10.1177/23337214231158476. PMID: 36860700.
• Moore 2012. 2012. DOI: 10.1371/journal.pmed.1001335. PMID: 23139642.
• Mora-Gonzalez 2020. 2020. DOI: 10.3390/ijerph17030877. PMID: 32019259.
• Mortensen 2022. 2022. DOI: 10.1136/bmjdrc-2022-002935. PMID: 35977754.
• Wang 2025. 2025. DOI: 10.3389/fspor.2025.1545481. PMID: 40230376.
• Silva 2019. 2019. DOI: 10.1186/s12889-019-7062-0. PMID: 31174515.
• Dogra 2012. 2012. DOI: 10.1155/2012/190654. PMID: 22997579.
• Vidoni 2015. 2015. DOI: 10.1371/journal.pone.0131647. PMID: 26158265.
• Moschny 2011. 2011. DOI: 10.1186/1479-5868-8-121. PMID: 22047024.
• Petersen 2020. 2020. DOI: 10.1186/s12966-020-01067-7. PMID: 33276796.
• Gheysen 2018. 2018. DOI: 10.1186/s12966-018-0697-x. PMID: 29973193.
• Maginador 2020. 2020. DOI: 10.3390/cancers12082240. PMID: 32796499.
• Maruf 2023. 2023. DOI: 10.1186/s13102-023-00622-6. PMID: 36879328.
• Izzicupo 2021. 2021. DOI: 10.3389/fspor.2021.624449. PMID: 33842880.
• Takahashi 2018. 2018. DOI: 10.3390/nu10111735. PMID: 30424505.
• Steene-Johannessen 2020. 2020. DOI: 10.1186/s12966-020-00930-x. PMID: 32183834.
• Cai 2025. 2025. DOI: 10.3389/fpubh.2025.1635020. PMID: 40910062.
• Hongu 2019. 2019. DOI: 10.3390/sports7010023. PMID: 30669254.
• Dorsman 2020. 2020. DOI: 10.3389/fnagi.2020.00104. PMID: 32410981.
• Acree 2006. 2006. DOI: 10.1186/1477-7525-4-37. PMID: 16813655.
• Fortier 2022. 2022. DOI: 10.7717/peerj.13832. PMID: 36093334.
• Vicente-Gabriel 2024. 2024. DOI: 10.3389/fpubh.2024.1322437. PMID: 38344236.
• Szalo 2021. 2021. DOI: 10.1186/s12872-021-01911-z. PMID: 33593279.
• Tucker 2023. 2023. DOI: 10.3390/children11010022. PMID: 38255336.
• Gomez-Sanchez 2023. 2023. DOI: 10.31083/j.rcm2411318. PMID: 39076448.
• Barnett 2017. 2017. DOI: 10.1186/s12966-017-0558-z. PMID: 28784183.
• Zheng 2019. 2019. DOI: 10.3389/fnagi.2019.00098. PMID: 31080412.
• Ekelund 2019. 2019. DOI: 10.1136/bmj.l4570. PMID: 31434697.
• Schoemaker 2019. 2019. DOI: 10.3390/ijerph17010098. PMID: 31877803.
• Eades 2021. 2021. DOI: 10.1038/s41598-021-94164-x. PMID: 34290291.
• Neophytou 2024. 2024. DOI: 10.17159/2078-516X/2024/v36i1a15245. PMID: 38384860.
• Hart 2011. 2011. DOI: 10.1186/1479-5868-8-62. PMID: 21679426.
• Albrecht 2020. 2020. DOI: 10.1371/journal.pone.0228053. PMID: 31978178.
• Sloan 2022. 2022. DOI: 10.2196/34717. PMID: 35793133.
• Cefis 2025. 2025. DOI: 10.1016/j.xcrm.2025.101968. PMID: 39933528.
• Mello 2025. 2025. DOI: 10.1371/journal.pone.0317578. PMID: 40138302.
• AOYAMA 2025. 2025. DOI: 10.1249/MSS.0000000000003902. PMID: 41289170.
• Janssen 2010. 2010. DOI: 10.1186/1479-5868-7-40. PMID: 20459784.
• Salisbury 2023. 2023. DOI: 10.3390/jvd2030027. PMID: 39328309.
• Rogers 2017. 2017. DOI: 10.1371/journal.pone.0170878. PMID: 28152084.
• Awuviry-Newton 2023. 2023. DOI: 10.1371/journal.pgph.0001014. PMID: 36963038.
• Luijk 2024. 2024. DOI: 10.1177/20552076241286641. PMID: 39421312.
• Zeng 2025. 2025. DOI: 10.1093/geroni/igaf122.2376.
• Melby 2022. 2022. DOI: 10.1186/s12889-022-13517-x. PMID: 35768864.
• Donath 2017. 2017. DOI: 10.1186/s12877-017-0634-x. PMID: 29070027.
• Elias 2021. 2021. DOI: 10.3389/fcvm.2021.740442. PMID: 34977170.
• Mauro 2022. 2022. DOI: 10.7717/peerj.14123. PMID: 36213500.
• Murlasits 2022. 2022. DOI: 10.1136/bmjsem-2022-001458. PMID: 36484059.
• Ramos 2026. 2026. DOI: 10.1155/jare/8981398. PMID: 41972113.
• McPhee 2016. 2016. DOI: 10.1007/s10522-016-9641-0. PMID: 26936444.
• Thomas 2021. 2021. DOI: 10.1038/s41598-021-87914-4. PMID: 33875729.
• Jaakkola 2022. 2022. DOI: 10.1093/eurpub/ckac095.042.
• Li 2023. 2023. DOI: 10.3389/fspor.2022.1036777. PMID: 36699982.
• Hart 2025. 2025. DOI: 10.1093/geroni/igaf122.4005.

Background References

Canonical background sources cited in the public manuscript.

• ADA 2024. American Diabetes Association. Standards of Care in Diabetes. Diabetes Care. 2024;47(Suppl 1). DOI: 10.2337/dc24-S006.
• Cruz-Jentoft 2019. Cruz-Jentoft AJ, Bahat G, Bauer J, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019;48(1):16-31. DOI: 10.1093/ageing/afy169. PMID: 30312372.
• Ioannidis 2005. Ioannidis JPA. Why most published research findings are false. PLoS Med. 2005;2(8):e124. DOI: 10.1371/journal.pmed.0020124. PMID: 16060722.